Rapid-onset antidepressant action of ketamine: potential revolution in understanding and future pharmacologic treatment of depression

In Vivo Ketamine-Induced Changes in [ 11 C]ABP688 Binding to Metabotropic Glutamate Receptor Subtype 5

(2015) Christine DeLorenzo et al.   BIOLOGICAL PSYCHIATRY

Mechanisms underlying differential effectiveness of memantine and ketamine in rapid antidepressant responses

(2014) E. S. Gideons et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

GABA/glutamate co-release controls habenula output and is modified by antidepressant treatment

(2014) S. J. Shabel et al.   SCIENCE

Ketamine as Antidepressant? Current State and Future Perspectives

(2013) H. Hasselmann   Current Neuropharmacology

GLYX-13, an NMDA receptor glycine site functional partial agonist enhances cognition and produces antidepressant effects without the psychotomimetic side effects of NMDA receptor antagonists

(2013) Joseph R Moskal et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Repeated S-ketamine Infusions in Therapy Resistant Depression: A Case Series

(2013) Felix Segmiller et al.   JOURNAL OF CLINICAL PHARMACOLOGY

GLYX-13, a NMDA Receptor Glycine-Site Functional Partial Agonist, Induces Antidepressant-Like Effects Without Ketamine-Like Side Effects

(2013) Jeffrey Burgdorf et al.   NEUROPSYCHOPHARMACOLOGY

R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S (+)-ketamine

(2013) Ji-chun Zhang et al.   PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

(2013) Luli Akinfiresoye et al.   PSYCHOPHARMACOLOGY

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

(2013) Caroline A. Browne et al.   Frontiers in Pharmacology

The Role of Eukaryotic Elongation Factor 2 Kinase in Rapid Antidepressant Action of Ketamine

(2012) Lisa M. Monteggia et al.   BIOLOGICAL PSYCHIATRY

Rapid and Longer-Term Antidepressant Effects of Repeated Ketamine Infusions in Treatment-Resistant Major Depression

(2012) James W. Murrough et al.   BIOLOGICAL PSYCHIATRY

Effectiveness of a Breath-Actuated Nebulizer Device on Asthma Care in the Pediatric Emergency Department

(2012) M. Olivia Titus et al.   CLINICAL PEDIATRICS

Single ketamine infusion in bipolar depression resistant to antidepressants: are neurotrophins involved?

(2012) Janusz K. Rybakowski et al.   HUMAN PSYCHOPHARMACOLOGY-CLINICAL AND EXPERIMENTAL

Concomitant BDNF and sleep slow wave changes indicate ketamine-induced plasticity in major depressive disorder

(2012) Wallace C. Duncan et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990–2010: a systematic analysis for the Global Burden of Disease Study 2010

(2012) Theo Vos et al.   LANCET

Course of Improvement in Depressive Symptoms to a Single Intravenous Infusion of Ketamine vs Add-on Riluzole: Results from a 4-Week, Double-Blind, Placebo-Controlled Study

(2012) Lobna Ibrahim et al.   NEUROPSYCHOPHARMACOLOGY

A Systematic Review of Comparative Efficacy of Treatments and Controls for Depression

(2012) Arif Khan et al.   PLoS One

Ketamine use: a review

(2011) Celia J. A. Morgan et al.   ADDICTION

Reduced Metabotropic Glutamate Receptor 5 Density in Major Depression Determined by [11C]ABP688 PET and Postmortem Study

(2011) Alexandra Deschwanden et al.   AMERICAN JOURNAL OF PSYCHIATRY

Intravenous Ketamine for Treatment-Resistant Major Depressive Disorder

(2011) Jordan R Covvey et al.   ANNALS OF PHARMACOTHERAPY

Involvement of AMPA receptor in both the rapid and sustained antidepressant-like effects of ketamine in animal models of depression

(2011) Hiroyuki Koike et al.   BEHAVIOURAL BRAIN RESEARCH

Ketamine as a Novel Antidepressant: From Synapse to Behavior

(2011) J W Murrough   CLINICAL PHARMACOLOGY & THERAPEUTICS

Memantine for late-life depression and apathy after a disabling medical event: a 12-week, double-blind placebo-controlled pilot study

(2011) Eric J. Lenze et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Inhibition of glycogen synthase kinase-3 is necessary for the rapid antidepressant effect of ketamine in mice

(2011) E Beurel et al.   MOLECULAR PSYCHIATRY

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

(2011) Anita E. Autry et al.   NATURE

The mTOR signaling pathway in the prefrontal cortex is compromised in major depressive disorder

(2011) Courtney S. Jernigan et al.   PROGRESS IN NEURO-PSYCHOPHARMACOLOGY & BIOLOGICAL PSYCHIATRY

Magnetic Resonance Spectroscopy Studies of Glutamate-Related Abnormalities in Mood Disorders

(2010) Cagri Yüksel et al.   BIOLOGICAL PSYCHIATRY

Antidepressant Drug Effects and Depression Severity

(2010) Jay C. Fournier et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Lithium’s Emerging Role in the Treatment of Refractory Major Depressive Episodes: Augmentation of Antidepressants

(2010) Michael Bauer et al.   NEUROPSYCHOBIOLOGY

mTOR-Dependent Synapse Formation Underlies the Rapid Antidepressant Effects of NMDA Antagonists

(2010) N. Li et al.   SCIENCE

Deficit in BDNF does not increase vulnerability to stress but dampens antidepressant-like effects in the unpredictable chronic mild stress

(2009) Yadira Ibarguen-Vargas et al.   BEHAVIOURAL BRAIN RESEARCH

Safety and Efficacy of Repeated-Dose Intravenous Ketamine for Treatment-Resistant Depression

(2009) Marije aan het Rot et al.   BIOLOGICAL PSYCHIATRY

Role of Brain-Derived Neurotrophic Factor in the Aetiology of Depression

(2009) Eero Castrén et al.   CNS DRUGS

Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial

(2009) Sanjay J. Mathew et al.   INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY

mTOR signaling: At the crossroads of plasticity, memory and disease

(2009) Charles A. Hoeffer et al.   TRENDS IN NEUROSCIENCES

Difference in Treatment Outcome in Outpatients With Anxious Versus Nonanxious Depression: A STAR*D Report

(2008) Maurizio Fava et al.   AMERICAN JOURNAL OF PSYCHIATRY

Amino Acid Neurotransmitters Assessed by Proton Magnetic Resonance Spectroscopy: Relationship to Treatment Resistance in Major Depressive Disorder

(2008) Rebecca B. Price et al.   BIOLOGICAL PSYCHIATRY

Comparison of racemic ketamine andS-ketamine in treatment-resistant major depression: Report of two cases

(2008) Robert Paul et al.   WORLD JOURNAL OF BIOLOGICAL PSYCHIATRY

Cellular Mechanisms Underlying the Antidepressant Effects of Ketamine: Role of α-Amino-3-Hydroxy-5-Methylisoxazole-4-Propionic Acid Receptors

(2007) Sungho Maeng et al.   BIOLOGICAL PSYCHIATRY